Brief: Phathom Pharmaceuticals Announces FDA Acceptance Of NDA Resubmission For Erosive GERD
12/06/2023 14:35
June 12 (Reuters) - Phathom Pharmaceuticals Inc
PHAT.O :
* PHATHOM PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF NDA
RESUBMISSION FOR EROSIVE GERD
* PHATHOM PHARMACEUTICALS INC - PRESCRIPTION DRUG USER FEE
ACT
(PDUFA) GOAL DATE OF NOVEMBER 17, 2023
* PHATHOM PHARMACEUTICALS INC - COMBINED LAUNCH OF
VONOPRAZAN FOR
EROSIVE GERD AND H. PYLORI INDICATIONS PLANNED FOR Q4 2023, IF
APPROVED
Source text for Eikon: ID:nGNX7WSq3V
Further company coverage: PHAT.O
(reuters.briefs@thomsonreuters.com)
Recent news on Phathom Pharmaceuticals
See all newsBrief: Phathom Pharma Provides Update On Litigation Filed By BDR Pharma Against FDA
Phathom Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Phathom Pharmaceuticals Q2 revenue beats on Voquezna prescription growth
Brief: Phathom Pharmaceuticals Q2 Net Income USD -17.582 Million
Phathom Pharmaceuticals Q1 revenue more than doubles, beats estimates